Clarity Pharmaceuticals Ltd has released a press release.
Appendix 4D
Filed with ASX ·
On 6ix: 6ix.com/news/appendix-4d-22
6ix hasn’t read this filing yet.
Clarity Pharmaceuticals Ltd. on 6ix
Earlier from Clarity Pharmaceuticals
- Clarity receives US FDA Fast Track Designation for the treatment of metastatic castration-resistant prostate cancer patients with Cu-67 SAR-bisPSMA
- Clarity receives US FDA FTD for the treatment of mCRPC
- Clarity expands pipeline with Cu-64/67 SAR-trastuzumab
- Clarity to present COBRA and CLARIFY abstracts
- Clarity receives U.S. FDA Fast Track Designation
Later from Clarity Pharmaceuticals
- Clarity signs Cu-64 Supply Agreement with UQ
- SECuRE trial update: 92% of pre-chemo participants experience greater than 35% drop in PSA levels across all cohorts. Cohort Expansion Phase commences.
- First patient treated in the Phase II of the SECuRE trial
- SECuRE trial update: First patient treated in the Phase II Cohort Expansion
- $11.1 million RDTI and refocus on high-priority programs
Follow Clarity Pharmaceuticals into a list and get an email when it puts out news.
Follow Clarity Pharmaceuticals